Quoted from the ClinicalTrials.gov Glossary.
For additional information, see The Genes, Environment and Health Initiative (GEI) archived webpage.
Quoted from NIH 's National Human Genome Research Institute's Talking Glossary of Genetic Terms.
For additional information, visit NCI's Geographic Information System and Science for Cancer Control website.
The principles of GCP help assure the safety, integrity, and quality of clinical trials. GCP provides a standard for ensuring clinical trial compliance, implementation, data collection, monitoring, and reporting (e.g., safety data, accrual reports, study status, protocol deviations, unanticipated problems, or final data), and outline the responsibilities of Institutional Review Boards (IRBs), investigators, sponsors and monitors. GCP addresses elements related to the design, conduct and reporting (e.g., safety data, accrual reports, study status, protocol deviations, unanticipated problems, or final data) of clinical trials.
Acceptable GCP courses include the "NIAID GCP Learning Center website" and "National Drug Abuse Treatment Clinical Trials Network".
Excerpted from NIH Guide Notice NOT-OD-16-148 "Policy on Good Clinical Practice Training for NIH Awardees Involved in NIH-funded Clinical Trials".
The regulations set forth in 21 CFR 212 apply to current good manufacturing practice for Positron Emission Tomography (PET) drugs.
On January 4, 2011, the President signed into law the GPRA Modernization Act of 2010 (Public Law 111-352).
For additional information, see the NIH Division of Program Coordination, Planning and Strategic Initiatives (DPCPSI), Office of Program Evaluation and Performance, NIH Performance Reporting webpage.
Quoted from §45.101 of the Federal Acquisition Regulation
For additional information, contact your division's travel planner or visit the GSA's Plan and Book webpage.
Quoted from §45.101 of the Federal Acquisition Regulation.
Quoted from §2.101 of the Federal Acquisition Regulation.
Quoted from the NIH OER Glossary & Acronym List
For a complete overview of NIH Grants, visit the NIH OER About Grants webpage.
(1) Is used to enter into a relationship the principal purpose of which is to transfer anything of value from the Federal awarding agency or pass-through entity to the non-Federal entity to carry out a public purpose authorized by a law of the United States (see 31 U.S.C. §6101(3)); and not to acquire property or services for the Federal awarding agency or pass-through entity's direct benefit or use;
(2) Is distinguished from a cooperative agreement in that it does not provide for substantial involvement between the Federal awarding agency or pass-through entity and the non-Federal entity in carrying out the activity contemplated by the Federal award.
(3) Does not include an agreement that provides only:
Quoted from 45 CFR §75.2.
Quoted from the NIH OER Glossary & Acronym List.
See also "Learn more about the grant closeout process".
Quoted from the NCI Grants Process Quick Overview webpage.
Quoted from the NIH OER Glossary & Acronym List.
The Signing Official and PI can view Grant Folder via the Commons PI View.
Excerpted from the eRA Grant Folder – Overview webpage.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from the NIH OER Glossary & Acronym List.
Quoted from NIH Guide Notice NOT-OD-11-064.